| Arun S Patil, MD | |
|
10815 W Mcdowell Rd, Suite 202, Avondale, AZ 85392 | |
| (623) 433-0202 | |
| (623) 433-0204 |
| Full Name | Arun S Patil |
|---|---|
| Gender | Male |
| Speciality | Interventional Cardiology |
| Experience | 36 Years |
| Location | 10815 W Mcdowell Rd, Avondale, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093955908 | NPI | - | NPPES |
| 695171 | Medicaid | AZ |
| Facility Name | Location | Facility Type |
|---|---|---|
| Summit Healthcare Regional Medical Center | Show low, AZ | Hospital |
| St. Joseph's Hospital And Medical Center | Phoenix, AZ | Hospital |
| Banner Estrella Medical Center | Phoenix, AZ | Hospital |
| Banner Payson Medical Center | Payson, AZ | Hospital |
| Yuma Regional Medical Center | Yuma, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Integrated Medical Services Inc | 1052328408 | 74 |
| Sjhmc Physician Services | 4486646197 | 533 |
| Summit Healthcare Association | 3779568647 | 80 |
| Summit Healthcare Medical Associates | 8729205737 | 76 |
News Archive
NexMed, Inc, a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Company has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) for a Phase II trial of its recently acquired cancer drug candidate PrevOnco™, in combination with doxorubicin in patients with advanced, unresectable hepatocellular carcinoma (HCC). The FDA has 30 days to comment on the IND before NexMed can proceed with human testing.
A new development in engineering chimeric antigen receptor (CAR) T cells, called affinity tuning, can make the CAR T cells spare normal cells and better recognize and attack cancer cells, which may help lower the toxicity associated with this type of immunotherapy when used against solid tumors, according to a preclinical study.
Leica Microsystems announce the launch of its clinical workflow solution for Digital Pathology at Pathology Visions 2011. Digital Image Hub Enterprise* with its powerful image management, integration and communication capabilities, in conjunction with a new high performance, intuitive client viewer, SlidePath Gateway*, combine to make this the ideal solution for clinical centers moving towards true Digital Pathology implementation. Furthermore, Leica's Total Digital Pathology solutions now provide an implementation of the DICOM Supplement 145 standard for both slide scanning and viewing.
News outlets continue to examine statements made in the presidential debate as they look ahead to Thursday nights vice-presidential debate.
› Verified 1 days ago
| Entity Name | La Paz Regional Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083639983 PECOS PAC ID: 1557273356 Enrollment ID: O20031219000694 |
News Archive
NexMed, Inc, a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Company has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) for a Phase II trial of its recently acquired cancer drug candidate PrevOnco™, in combination with doxorubicin in patients with advanced, unresectable hepatocellular carcinoma (HCC). The FDA has 30 days to comment on the IND before NexMed can proceed with human testing.
A new development in engineering chimeric antigen receptor (CAR) T cells, called affinity tuning, can make the CAR T cells spare normal cells and better recognize and attack cancer cells, which may help lower the toxicity associated with this type of immunotherapy when used against solid tumors, according to a preclinical study.
Leica Microsystems announce the launch of its clinical workflow solution for Digital Pathology at Pathology Visions 2011. Digital Image Hub Enterprise* with its powerful image management, integration and communication capabilities, in conjunction with a new high performance, intuitive client viewer, SlidePath Gateway*, combine to make this the ideal solution for clinical centers moving towards true Digital Pathology implementation. Furthermore, Leica's Total Digital Pathology solutions now provide an implementation of the DICOM Supplement 145 standard for both slide scanning and viewing.
News outlets continue to examine statements made in the presidential debate as they look ahead to Thursday nights vice-presidential debate.
› Verified 1 days ago
| Entity Name | Sjhmc Physician Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326098005 PECOS PAC ID: 4486646197 Enrollment ID: O20040401001189 |
News Archive
NexMed, Inc, a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Company has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) for a Phase II trial of its recently acquired cancer drug candidate PrevOnco™, in combination with doxorubicin in patients with advanced, unresectable hepatocellular carcinoma (HCC). The FDA has 30 days to comment on the IND before NexMed can proceed with human testing.
A new development in engineering chimeric antigen receptor (CAR) T cells, called affinity tuning, can make the CAR T cells spare normal cells and better recognize and attack cancer cells, which may help lower the toxicity associated with this type of immunotherapy when used against solid tumors, according to a preclinical study.
Leica Microsystems announce the launch of its clinical workflow solution for Digital Pathology at Pathology Visions 2011. Digital Image Hub Enterprise* with its powerful image management, integration and communication capabilities, in conjunction with a new high performance, intuitive client viewer, SlidePath Gateway*, combine to make this the ideal solution for clinical centers moving towards true Digital Pathology implementation. Furthermore, Leica's Total Digital Pathology solutions now provide an implementation of the DICOM Supplement 145 standard for both slide scanning and viewing.
News outlets continue to examine statements made in the presidential debate as they look ahead to Thursday nights vice-presidential debate.
› Verified 1 days ago
| Entity Name | Summit Healthcare Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144209271 PECOS PAC ID: 3779568647 Enrollment ID: O20040623001125 |
News Archive
NexMed, Inc, a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Company has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) for a Phase II trial of its recently acquired cancer drug candidate PrevOnco™, in combination with doxorubicin in patients with advanced, unresectable hepatocellular carcinoma (HCC). The FDA has 30 days to comment on the IND before NexMed can proceed with human testing.
A new development in engineering chimeric antigen receptor (CAR) T cells, called affinity tuning, can make the CAR T cells spare normal cells and better recognize and attack cancer cells, which may help lower the toxicity associated with this type of immunotherapy when used against solid tumors, according to a preclinical study.
Leica Microsystems announce the launch of its clinical workflow solution for Digital Pathology at Pathology Visions 2011. Digital Image Hub Enterprise* with its powerful image management, integration and communication capabilities, in conjunction with a new high performance, intuitive client viewer, SlidePath Gateway*, combine to make this the ideal solution for clinical centers moving towards true Digital Pathology implementation. Furthermore, Leica's Total Digital Pathology solutions now provide an implementation of the DICOM Supplement 145 standard for both slide scanning and viewing.
News outlets continue to examine statements made in the presidential debate as they look ahead to Thursday nights vice-presidential debate.
› Verified 1 days ago
| Entity Name | St. Joseph's Hospital And Medical Center C/o Dignity Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255382412 PECOS PAC ID: 6709863178 Enrollment ID: O20040702000601 |
News Archive
NexMed, Inc, a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Company has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) for a Phase II trial of its recently acquired cancer drug candidate PrevOnco™, in combination with doxorubicin in patients with advanced, unresectable hepatocellular carcinoma (HCC). The FDA has 30 days to comment on the IND before NexMed can proceed with human testing.
A new development in engineering chimeric antigen receptor (CAR) T cells, called affinity tuning, can make the CAR T cells spare normal cells and better recognize and attack cancer cells, which may help lower the toxicity associated with this type of immunotherapy when used against solid tumors, according to a preclinical study.
Leica Microsystems announce the launch of its clinical workflow solution for Digital Pathology at Pathology Visions 2011. Digital Image Hub Enterprise* with its powerful image management, integration and communication capabilities, in conjunction with a new high performance, intuitive client viewer, SlidePath Gateway*, combine to make this the ideal solution for clinical centers moving towards true Digital Pathology implementation. Furthermore, Leica's Total Digital Pathology solutions now provide an implementation of the DICOM Supplement 145 standard for both slide scanning and viewing.
News outlets continue to examine statements made in the presidential debate as they look ahead to Thursday nights vice-presidential debate.
› Verified 1 days ago
| Entity Name | Integrated Medical Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760441141 PECOS PAC ID: 1052328408 Enrollment ID: O20060309000742 |
News Archive
NexMed, Inc, a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Company has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) for a Phase II trial of its recently acquired cancer drug candidate PrevOnco™, in combination with doxorubicin in patients with advanced, unresectable hepatocellular carcinoma (HCC). The FDA has 30 days to comment on the IND before NexMed can proceed with human testing.
A new development in engineering chimeric antigen receptor (CAR) T cells, called affinity tuning, can make the CAR T cells spare normal cells and better recognize and attack cancer cells, which may help lower the toxicity associated with this type of immunotherapy when used against solid tumors, according to a preclinical study.
Leica Microsystems announce the launch of its clinical workflow solution for Digital Pathology at Pathology Visions 2011. Digital Image Hub Enterprise* with its powerful image management, integration and communication capabilities, in conjunction with a new high performance, intuitive client viewer, SlidePath Gateway*, combine to make this the ideal solution for clinical centers moving towards true Digital Pathology implementation. Furthermore, Leica's Total Digital Pathology solutions now provide an implementation of the DICOM Supplement 145 standard for both slide scanning and viewing.
News outlets continue to examine statements made in the presidential debate as they look ahead to Thursday nights vice-presidential debate.
› Verified 1 days ago
| Entity Name | Sierra Vista Regional Health Center Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043575483 PECOS PAC ID: 3779732854 Enrollment ID: O20121004000679 |
News Archive
NexMed, Inc, a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Company has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) for a Phase II trial of its recently acquired cancer drug candidate PrevOnco™, in combination with doxorubicin in patients with advanced, unresectable hepatocellular carcinoma (HCC). The FDA has 30 days to comment on the IND before NexMed can proceed with human testing.
A new development in engineering chimeric antigen receptor (CAR) T cells, called affinity tuning, can make the CAR T cells spare normal cells and better recognize and attack cancer cells, which may help lower the toxicity associated with this type of immunotherapy when used against solid tumors, according to a preclinical study.
Leica Microsystems announce the launch of its clinical workflow solution for Digital Pathology at Pathology Visions 2011. Digital Image Hub Enterprise* with its powerful image management, integration and communication capabilities, in conjunction with a new high performance, intuitive client viewer, SlidePath Gateway*, combine to make this the ideal solution for clinical centers moving towards true Digital Pathology implementation. Furthermore, Leica's Total Digital Pathology solutions now provide an implementation of the DICOM Supplement 145 standard for both slide scanning and viewing.
News outlets continue to examine statements made in the presidential debate as they look ahead to Thursday nights vice-presidential debate.
› Verified 1 days ago
| Entity Name | Summit Healthcare Medical Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467878108 PECOS PAC ID: 8729205737 Enrollment ID: O20140815000931 |
News Archive
NexMed, Inc, a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Company has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) for a Phase II trial of its recently acquired cancer drug candidate PrevOnco™, in combination with doxorubicin in patients with advanced, unresectable hepatocellular carcinoma (HCC). The FDA has 30 days to comment on the IND before NexMed can proceed with human testing.
A new development in engineering chimeric antigen receptor (CAR) T cells, called affinity tuning, can make the CAR T cells spare normal cells and better recognize and attack cancer cells, which may help lower the toxicity associated with this type of immunotherapy when used against solid tumors, according to a preclinical study.
Leica Microsystems announce the launch of its clinical workflow solution for Digital Pathology at Pathology Visions 2011. Digital Image Hub Enterprise* with its powerful image management, integration and communication capabilities, in conjunction with a new high performance, intuitive client viewer, SlidePath Gateway*, combine to make this the ideal solution for clinical centers moving towards true Digital Pathology implementation. Furthermore, Leica's Total Digital Pathology solutions now provide an implementation of the DICOM Supplement 145 standard for both slide scanning and viewing.
News outlets continue to examine statements made in the presidential debate as they look ahead to Thursday nights vice-presidential debate.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Arun S Patil, MD 3815 E Bell Rd Ste 2200, Phoenix, AZ 85032-2139 Ph: (602) 633-3848 | Arun S Patil, MD 10815 W Mcdowell Rd, Suite 202, Avondale, AZ 85392 Ph: (623) 433-0202 |
News Archive
NexMed, Inc, a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the Company has filed an Investigational New Drug (IND) application with the U.S. Food & Drug Administration (FDA) for a Phase II trial of its recently acquired cancer drug candidate PrevOnco™, in combination with doxorubicin in patients with advanced, unresectable hepatocellular carcinoma (HCC). The FDA has 30 days to comment on the IND before NexMed can proceed with human testing.
A new development in engineering chimeric antigen receptor (CAR) T cells, called affinity tuning, can make the CAR T cells spare normal cells and better recognize and attack cancer cells, which may help lower the toxicity associated with this type of immunotherapy when used against solid tumors, according to a preclinical study.
Leica Microsystems announce the launch of its clinical workflow solution for Digital Pathology at Pathology Visions 2011. Digital Image Hub Enterprise* with its powerful image management, integration and communication capabilities, in conjunction with a new high performance, intuitive client viewer, SlidePath Gateway*, combine to make this the ideal solution for clinical centers moving towards true Digital Pathology implementation. Furthermore, Leica's Total Digital Pathology solutions now provide an implementation of the DICOM Supplement 145 standard for both slide scanning and viewing.
News outlets continue to examine statements made in the presidential debate as they look ahead to Thursday nights vice-presidential debate.
› Verified 1 days ago
Dr. Vikram Kapur, M.D Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 10450 W Mcdowell Rd, Suite 101, Avondale, AZ 85392 Phone: 623-935-1000 Fax: 623-935-1022 | |
Dr. Hursh Naik, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 10815 W Mcdowell Rd Ste 202, Avondale, AZ 85392 Phone: 623-433-0202 Fax: 623-433-0204 | |
Adhar Seth, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 10815 W Mcdowell Rd, Suite 202, Avondale, AZ 85392 Phone: 623-433-0202 Fax: 623-433-0204 | |
Melanie Noel Hernandez, FNP-C Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 10450 W Mcdowell Rd Ste 101, Avondale, AZ 85392 Phone: 623-935-1000 | |
Dr. Kathleen A Nichols, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 13055 W Mcdowell Rd, Suite E-106, Avondale, AZ 85392 Phone: 623-975-8400 Fax: 623-935-2975 | |
Mr. Devendra V Gulaya, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 10320 W Mcdowell Rd, Bldg N1445, Avondale, AZ 85392 Phone: 623-547-2100 Fax: 623-547-3005 |